Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.63 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.63 |
| ▸ | DGAT1 | O75907 | 14/20 | 0.61 |
| ▸ | NNMT | P40261 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16661050 | 0.90 | DGAT1 (0.59) | MKNK1MKNK2DGAT1AAK1 | |
| SCHEMBL16660930 | 0.89 | DGAT1 (0.58) | MKNK1MKNK2DGAT1NNMTSOAT1 | |
| SCHEMBL18541134 | 0.89 | DGAT1 (0.62) | MKNK1MKNK2DGAT1SOAT1KCNH2 | |
| SCHEMBL16661033 | 0.89 | DGAT1 (0.62) | MKNK1MKNK2DGAT1SOAT1KCNH2 | |
| SCHEMBL10007447 | 0.87 | DGAT1 (0.60) | MKNK1MKNK2DGAT1SOAT1KCNH2 | |
| SCHEMBL16661020 | 0.85 | DGAT1 (0.59) | MKNK1MKNK2DGAT1SOAT1KCNH2 | |
| SCHEMBL20428788 | 0.85 | DGAT1 (0.54) | MKNK1MKNK2DGAT1AAK1 | |
| SCHEMBL16661278 | 0.84 | DGAT1 (0.58) | MKNK1MKNK2DGAT1SOAT1KCNH2 | |
| SCHEMBL20428515 | 0.84 | DGAT1 (0.58) | MKNK1MKNK2DGAT1SOAT1KCNH2 | |
| SCHEMBL10176555 | 0.83 | DGAT1 (0.52) | MKNK1MKNK2DGAT1NNMTSOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308636-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-04 | — | — | US | disclosed |
| EP-2862856-B1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-08-01 | — | — | EP | disclosed |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-9546155-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| US-9546155-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-06-11 | — | — | US | disclosed |
| EP-2862856-A1 | AROMATIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | MKNK1 3972/4885MKNK2 3986/4885DGAT1 1688/4885 |
| US-10308636-B2 | Aromatic heterocyclic compound | GPR119, NR0B1, BET1 | MKNK1 3972/4885MKNK2 3986/4885DGAT1 1688/4885 |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | MKNK1 3972/4885MKNK2 3986/4885DGAT1 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.